A publication concerning TAR-200 and nadofaragene firadenovec in BCG-unresponsive bladder carcinoma in situ was published on October 1, 2026. The article is titled "Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS." It appeared in the journal Anticancer Research. This entry reflects the publication record only, as cataloged under PubMed ID 42823172. No specific findings, outcomes, or data from the publication are detailed in this notice beyond its title, journal, and date. Lypressin carries an unapproved research status and is not addressed in this particular publication record. Readers interested in the subject matter of this publication can consult the listed source for the full article. For additional background and context on lypressin as a compound, readers may consult the compound overview.
Publication on TAR-200, Nadofaragene Firadenovec in Bladder CIS
See the full lypressin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42823172/